Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review.
Sudpreeda ChainitikunJose Rodrigo Espinosa FernandezJames P LongToshiaki IwaseKumiko KidaXiaoping WangSadia SaleemBora LimVicente ValeroNaoto Tada UenoPublished in: PloS one (2021)
Neoadjuvant chemotherapy plus targeted therapy is more effective than neoadjuvant chemotherapy alone for IBC patients. These findings support current IBC standard practice in particular the use of anti-HER2 targeted therapy.
Keyphrases
- neoadjuvant chemotherapy
- locally advanced
- lymph node
- sentinel lymph node
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- healthcare
- primary care
- rectal cancer
- peritoneal dialysis
- squamous cell carcinoma
- prognostic factors
- radiation therapy
- quality improvement
- early stage
- patient reported